Check for updates

OPEN ACCESS

EDITED BY Matthew Lee Smith, Texas A&M University, United States

REVIEWED BY Yang Song, Óbuda University, Hungary James David Adams, Independent Researcher, Benicia, CA, United States

*CORRESPONDENCE Yafei Zhang ⊠ 18601146@hebmu.edu.cn

[†]These authors have contributed equally to this work

RECEIVED 30 April 2024 ACCEPTED 24 July 2024 PUBLISHED 06 August 2024

CITATION

Chen J, Zhang M, Wang Y, Zhang Z, Gao S and Zhang Y (2024) The effect of Ba Duan Jin exercise intervention on cardiovascular disease: a meta-analysis of randomized controlled trials. *Front. Public Health* 12:1425843. doi: 10.3389/fpubh.2024.1425843

COPYRIGHT

© 2024 Chen, Zhang, Wang, Zhang, Gao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The effect of Ba Duan Jin exercise intervention on cardiovascular disease: a meta-analysis of randomized controlled trials

Jiali Chen^{1†}, Man Zhang^{2†}, Yihao Wang³, Ziyu Zhang³, Shuyan Gao¹ and Yafei Zhang⁴*

¹Global Medical Research Promotion, Graduate School of Medicine Science and Technology, Shinshu University, Matsumoto, Japan, ²Department of Physical Education, Hebei Medical University, Shijiazhuang, China, ³Nursing School, Graduate School, Hebei Medical University, Shijiazhuang, China, ⁴Department of Physical Education, Clinical College, Hebei Medical University, Shijiazhuang, China

Background: There is a growing interest in the use of complementary therapies for the prevention of disease and the maintenance of health. Furthermore, complementary therapies that incorporate exercise are becoming increasingly prevalent among the older adult, and thus may represent a crucial strategy for the primary and secondary prevention of cardiovascular disease (CVD). Exercise therapy, as a means to prevent and treat cardiovascular diseases, has been gradually applied in clinical practice. It has the advantages of reducing mortality, improving clinical symptoms, restoring physical function and improving quality of life. In recent years, traditional Chinese sports such as Ba Duan Jin and Qigong have developed rapidly. Therefore, a comprehensive systematic review is required to examine interventions involving Ba Duan Jin exercise in healthy adults or those at increased risk of CVD in order to determine the effectiveness of Ba Duan Jin exercise for the primary prevention of CVD.

Objective: To investigate the effect of Ba Duan Jin exercise intervention for the primary prevention of cardiovascular diseases.

Methods: Eight databases were systematically searched from inception to July, 2024 for randomized controlled trials (RCTs) to evaluated the impact of Ba Duan Jin exercise intervention on cardiovascular diseases. The search terms were "Cardiovascular diseases" "Ba Duan Jin" and "Randomized controlled." The Cochrane risk assessment tool was used to evaluate the study quality, and the meta-analysis was performed using Rev. Man 5.4 software.

Results: Seventeen completed trials were conducted with 1,755 participants who were randomly assigned and met the inclusion criteria. All 17 studies were conducted in China. The meta-analysis indicates that Ba Duan Jin exercise therapy can provide long-term benefits (20–30 years) by reducing all-cause mortality (RR = 0.55, 95% CI: 0.44–0.68, p < 0.01) and stroke mortality (RR = 0.49, 95% CI: 0.36–0.66, p < 0.01) in hypertensive patients. Subgroup analyses reveal that Ba Duan Jin exercise therapy decreases SBP (MD = -4.05, 95% CI = -6.84 to -1.26, p < 0.01) and DBP (MD = -3.21, 95% CI = -5.22 to -1.20, p < 0.01) levels in patients with essential hypertension, significantly reduces serum TC (MD = -0.78, 95% CI = -1.06 to -0.50, p < 0.01), TG (MD = -0.78, 95% CI = -0.93 to -0.62, p < 0.01), and LDL-C (MD = -0.76, 95% CI = -0.92 to -0.60, p < 0.01) levels in patients with hyperlipidemia, increases HDL-C (MD = 0.32, 95% CI = -3.84 to -0.44-0.51, p < 0.01) levels, and produces beneficial effects on cardiovascular function. Additionally, it can alleviate anxiety (MD = -3.37, 95% CI = -3.84 to

-2.89, p < 0.01) and improve sleep quality (MD = -2.68, 95% CI = -3.63to -1.73, p < 0.01).

Conclusion: Ba Duan Jin exercise therapy can improve the physical and mental condition and quality of life of patients with cardiovascular diseases, and it is worthy of further promotion and application in clinical practice.

Systematic review registration: PROSPERO, identifier: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024496934.

KEYWORDS

Ba Duan Jin, effect, cardiovascular diseases, systematic review, meta-analysis

1 Introduction

Cardiovascular diseases (CVDs) continue to be the primary cause of global deaths and disabilities. Over the past decade, the global number of deaths from CVD has increased by 12.5%, attributing to approximately one third of all deaths worldwide (1). The development of CVD is influenced by various factors including changes in health-related behaviors such as tobacco use, unhealthy diet, physical inactivity, alcohol consumption and high levels of stress. Each of these factors plays a significant role in the development and progression of CVD (2–4). Between 1990 and 2019, there was a significant increase in the number of deaths due to cardiovascular disease (CVD), rising from 12.1 million in 1990 to 18.6 million in 2019 (5). As a result, there is a growing need for public health interventions aimed at addressing the prevalence of CVD, and promoting healthier lifestyle choices to mitigate their impact.

Traditional Chinese exercise, such as Tai Chi and Qigong, has been extensively utilized in the management and treatment of various diseases. These exercises have shown positive effects in conditions like primary hypertension and cancer (6, 7). There is a widespread pandemic of physical inactivity that seems to mirror the high prevalence of cardiovascular disease (CVD). However, regular physical activity (PA) and exercise have a significant impact not only on primary cardiovascular prevention but also on secondary prevention (8–10). The Ba Duan Jin, also known as the Eight Section Brocade, is a traditional Chinese exercise that has been practiced for thousands of years. It is highly regarded as a valuable component of Chinese culture and is renowned for its health benefits (11). The practice of Ba Duan Jin is known to have positive effects on the mental, emotional, and social well-being of individuals (12). As a form of qigong, Ba Duan Jin is believed to facilitate the flow of qi, or life energy, throughout the body, which in turn contributes to improved health and vitality (13).

Ba Duan Jin has demonstrated promising results in enhancing various physical and neurological functions in patients. Research studies have indicated its potential to improve balance ability (14), motor skills, trunk stability (15), neurological functions (16), ability to perform daily living activities (17), and overall quality of life (18, 19). Additionally, it has been associated with reducing symptoms of anxiety and depression (20, 21). These findings suggest that Ba Duan Jin could be a valuable addition to rehabilitation and wellness programs for individuals seeking to improve their physical and mental well-being.

To date, there have been few randomized controlled trials (RCTs) investigating the effectiveness of Ba Duan Jin exercise for the prevention of cardiovascular disease (CVD), and even fewer systematic reviews exploring this topic. Three systematic reviews of interest examined the efficacy of Ba Duan Jin exercise for hypertension. The findings indicated that Ba Duan Jin exercise was associated with a reduction in blood pressure in individuals with hypertension (22). These findings are consistent with the findings of Bugni et al., which indicated that internal qigong was effective in decreasing blood pressure among those with essential hypertension when compared with no-treatment controls (23). However, it was not as effective as drug controls or conventional exercise controls. A further systematic review was conducted to assess the efficacy of Ba Duan Jin exercise in the management of essential hypertension (24). In comparison to control interventions, Ba Duan Jin exercise appears to be an efficacious physical exercise modality for the treatment of essential hypertension. The duration of the training period can influence the observed effects. Furthermore, a meta-analysis was conducted to investigate the impact of traditional Chinese exercises, namely Qigong and Tai Chi, on quality of life in individuals with essential hypertension. This systematic review and meta-analysis of randomized controlled trials suggests that Tai Chi may be an effective therapeutic approach to enhance quality of life in patients with essential hypertension (6).

It is notable that none of the above systematic reviews investigated the efficacy of Ba Duan Jin exercise therapy in the prevention of cardiovascular disease (6, 22–24). The main objective of this systematic review and meta-analysis is to investigate the efficacy of pure Ba Duan Jin exercise in the prevention of cardiovascular diseases, with the aim of providing new insights into the prevention of the cardiovascular system and managing cardiovascular health.

2 Methods

The study was conducted following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and was also registered on PROSPER (registration number: CRD42024496934).

2.1 Search strategy

The researchers conducted separate searches for English and Simplified Chinese studies related to the association between Ba Duan

10.3389/fpubh.2024.1425843

Jin and cardiovascular disease (CVD). They employed keywords such as Ba Duan Jin, Eight trigrams boxing, Cardiovascular Disease, and CVD to locate pertinent studies in various databases including PubMed, Cochrane Library, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Wan Fang Data, Chinese Science and Technology Journal Full-Text Database (VIP), and Chinese Biomedical Literature Database (CBM) to collect randomized controlled trials examining the impacts of Ba Duan Jin on cardiovascular disease, until July, 2024. Additionally, the reference lists of relevant publications were manually examined to uncover further studies. A detailed search strategy for PubMed was shown in Supplementary Table S1.

2.2 Criteria for inclusion

2.2.1 Types of studies

Randomized controlled trials (RCT).

2.2.2 Types of participant

Adults aged 18 years and older from the general population, as well as adults at high risk of cardiovascular disease (CVD), were included in the study.

2.2.3 Types of interventions

The experimental group received a single traditional Chinese exercise, such as Ba Duan Jin or qigong.

In order to avoid confounding, this review did not include multifactorial lifestyle intervention trials. The control interventions could be routine care or no intervention.

2.2.4 Types of outcome measures

2.2.4.1 Primary outcomes

All-cause mortality, stroke mortality, myocardial infarction mortality.

2.2.4.2 Secondary outcomes

Changes in blood pressure (systolic and diastolic blood pressure) and blood lipids [total cholesterol (TC), high-density lipid cholesterol (HDL-C), low-density lipid cholesterol (LDL-C)], triglycerides (TG), anxiety and sleep quality.

2.3 Criteria for exclusion

The study exclusion criteria were applied as follows: (1) Individuals with a history of myocardial infarction (MI), stroke, revascularization procedures (such as coronary artery bypass grafting or percutaneous transluminal coronary angioplasty), people with angina, or those with angiographically defined coronary heart disease (CHD). (2) The intervention did not match or combined with other interventions. (3) Studies published in books or conference proceedings. (4) Unavailability of the complete study.

2.4 Study selection

The search results were imported into Endnote software. Studies were independently screened by two researchers using the above inclusion criteria. Any differences between the two researchers are resolved through discussion with a third researcher. After culling duplicate studies, two researchers independently screened the titles and abstracts to exclude studies that did not meet the criteria. Then, read through the whole article again to weed out the appropriate research. In addition, the list of references included in the studies was used to search for more relevant studies.

2.5 Data extraction

Two researchers (CJL and ZM) compiled data in an Excel spreadsheet to facilitate the data extraction procedure. The primary investigators were also approached to obtain any supplementary relevant information. Information including author(year), study design, participant details, intervention, outcome data, adverse effects, and loss of follow-up were extracted from each study. Any discrepancies in the extracted data were resolved through consensus, with the involvement of a third author (ZZY) when needed.

2.6 Risk of bias assessment

The studies' quality was evaluated employing the Cochrane Risk of Bias assessment tool. The evaluation standards comprised random sequence generation, allocation concealment, blinding of participants and staff, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Two authors (CJL and ZM) independently assessed the risk of bias of included studies and rated each domain as having a low risk of bias, a high risk of bias or an unclear risk of bias.

2.7 Statistical analysis

Meta-analysis was performed using Rev. Man 5.4 and R4.3.2 software, with count data expressed as relative risk (*RR*) and 95% *CI*. Continuous variables such as SBP, DBP, TC, TG, LDL-C, HDL-C, SAS, and PSQI scores expressed as mean difference (*MD*) and 95% *CI*. If the Q-test p>0.05 and l^2 <50%, there was no statistically significant heterogeneity between studies, a fixed-effects model was used for meta-analysis. If p<0.05, l^2 >50%, there was greater heterogeneity between studies, the random-effects model was used to calculate the composite effect size, and the source of heterogeneity was further analyzed using meta-regression. Publication bias between studies was assessed using funnel plots and Egger's test, and for those with significant publication bias, the combined effect was analyzed by interpolation using the cut-and-patch method. Statistical significance was set at p<0.05.

3 Results

3.1 Selection outcomes

Upon conducting a database search, a total of 2,305 records were retrieved. After applying the inclusion criteria, 17 studies were deemed suitable for inclusion in the systematic review and meta-analysis. The study selection process is presented in Figure 1.



3.2 Study characteristics

Seventeen completed trials with 1755 participants who were randomly assigned and met the inclusion criteria. All 17 studies are from China. There was a difference in the health status of the participants between the trials. Two trials recruited healthy participants (25, 26), one trial recruited older adult people with high blood lipids (27), one trial recruited older adult people with pre-diabetes (28), and thirteen trials recruited hypertensive patients.

Follow-up periods varied among the included studies, ranging from 12 weeks (29–32) to 20 weeks (25), 24 weeks (33), 3 months (26, 34), 6 months (35–38), 1 year (28), and 18 months (27), to as long as 30 years in three studies (39–41).

The duration and frequency of Ba Duan Jin practice varied across the 17 studies analyzed. Seven studies (29, 31, 32, 36, 39–41) reported practicing Ba Duan Jin for 13–20 min per session, once or twice daily, five times a week. Among the five studies (30, 34, 35, 37, 38), the practice duration was 30–40 min, once or twice daily, five times a week. In the remaining four studies (25, 26, 28, 33), Ba Duan Jin was performed twice daily for 50–60 min, 5–7 times a week. Among the 17 studies, 10 used the Ba Duan Jin intervention, whereas the remaining 7 studies utilized the Ba Duan Jin-Qigong therapy intervention. Details of the included studies are provided in Supplementary Figure S1.

3.3 Assessment of the risks of study bias

Of the 17 RCTs included, 1 had a high risk of bias, 15 had an unclear risk of bias, and 1 had a low risk of bias. The study with high risk of bias was due to missing results because participants failed to complete the entire study during the experiment. Articles with unclear risk of bias were mainly due to insufficient information provided on the study methodology, especially in the areas of random sequence generation, allocation concealment, and participant blinding. In one trial, the research assistant who collected and entered the trial data remained blinded to group allocation throughout the trial, and this was considered to be at low risk of bias. The risk of bias in included studies was demonstrated in Figure 2. The risk of bias in individual trials was shown in Figure 3.

3.4 Meta-analysis results

3.4.1 Mortality

Based on the 17 completed included studies, three of them provided statistics on all-cause mortality, stroke mortality, and myocardial infarction (MI) mortality after 20 to 30 years of follow-up (39–41). However, it is unclear whether the Ba Duan Jin-Qigong intervention will continue over a period of 20 to 30 years.

In three trials (n=752), Ba Duan Jin exercise intervention significantly reduced all-cause mortality (RR=0.55, 95% *CI*: 0.44– 0.68, p<0.01). In three trials (n=752), Ba Duan Jin exercise intervention was found to significantly reduce stroke mortality (RR=0.49, 95% *CI*: 0.36–0.66, p<0.01). In three trials (n=752), Ba Duan Jin exercise intervention had no significant effect on mortality from MI (RR=0.61, 95% *CI*: 0.28–1.33, p=0.22) (Figure 4). The funnel plot suggested that there was no significant bias (Supplementary Figure S2). The sensitivity analysis suggested a better model robustness (Supplementary Figure S3).

3.4.2 Blood pressure

Twelve of the 17 included studies measured the effect of the Ba Duan Jin exercise intervention on participants' blood pressure (26, 28–38). Of the 17 included studies, 12 measured the effect of the Ba Duan Jin exercise intervention on subjects' blood pressure. Three studies investigated the long-term effects of the Ba Duan Jin exercise intervention on the systolic blood pressure (SBP) of the subjects and therefore only recorded blood pressure values before the start of the experiment and did not carry out blood pressure changes at the end of the intervention (39–41). A pooled analysis revealed a considerable degree of heterogeneity among the studies (P=67%, p=0.0004), as indicated by Egger's test (p=0.0129), the funnel plot results suggested a significant publication bias (Supplementary Figure S2). Firstly, the studies were interpolated by

the trim and fill method and then combined by a random effects model. The analysis of the results demonstrated a significant benefit of Ba Duan Jin exercise (MD=-4.05, 95% CI=-6.84 to -1.26, p<0.01) (Figure 5). The funnel plot after interpolation is presented in Supplementary Figure S4. The model demonstrated good robustness (Supplementary Figure S5). Meta-regression with age and number of participants, with female introduced as covariates, revealed that heterogeneity was fully explained (I^2 =0, p=0.9395, p=0.0008 for age).

A total of twelve trials (n = 873) were conducted to assess the effect of Ba Duan Jin exercise on blood pressure. The diastolic blood pressure (DBP) of participants was measured before and after the intervention. However, there was considerable heterogeneity among the studies $(I^2 = 60\%, p = 0.0042)$. The results of funnel plot suggested possible publication bias (Supplementary Figure S2). The same trim and fill method were employed to interpolate the studies prior to combining them in a random-effects model. The results are presented in Figure 5. The analysis of the results demonstrated a significant benefit of the Ba Duan Jin exercise (MD = -3.21, 95% CI = -5.22 to -1.20, p < 0.01). funnel plot after interpolation is presented The in Supplementary Figure S4. The model demonstrated good robustness (Supplementary Figure S5). A meta-regression incorporating age and the number of female participants as covariates demonstrated that heterogeneity was fully explained ($I^2 = 0, p = 0.5679$). However, age and the number of female participants were not statistically significant in the model. The results indicated that the Ba Duan Jin exercise intervention significantly reduced both SBP and DBP of the participants, thereby demonstrating a positive effect on blood pressure.

3.4.3 Total cholesterol

Eight trials (n=588) were conducted to assess the impact of the Ba Duan Jin exercise intervention on participants' total cholesterol (TC). The results demonstrated significant heterogeneity (I^2 = 69%, p=0.0011). However, publication bias was not statistically significant (Egger's test p=0.9985, Supplementary Figure S2). The effect sizes of the individual trials are presented in Figure 6. Six trials demonstrated a statistically significant reduction in total cholesterol with the Ba Duan Jin exercise intervention, while the remaining trial did not show a significant reduction in total cholesterol with the Ba Duan Jin exercise intervention (26, 34). Pooled analyses demonstrated that the Ba Duan Jin exercise intervention significantly reduced total



Over risk of bias: review authors' judgements about each risk of bias item for each included study.



Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. "+", low risk; "-", high risk; "?", unclear.

cholesterol levels in participants (MD = -0.78, 95% CI = -1.06 to -0.50, p < 0.01). Heterogeneity could be partially explained by introducing age and female for meta-regression ($I^2 = 29.93\%$, p = 0.2322). The sensitivity analysis suggested a better model robustness (Supplementary Figure 6).

3.4.4 Triglycerides

The results for triglycerides (TG) were similar to those for total cholesterol. No significant heterogeneity ($I^2 = 0, p = 0.50$) or bias (Egger's test, p = 0.2988, Supplementary Figure 2) were identified. The pooled results of nine studies (n = 636) indicated that the Ba Duan Jin exercise

intervention had a significant effect on triglyceride levels, with a mean difference of -0.78 (95% *CI* -0.93 to -0.62, p < 0.01). The intervention was found to have a significant effect on triglyceride levels, with a mean difference of -0.78 (95% *CI* -0.93 to -0.62, p < 0.01) (Figure 6). This could have a beneficial effect on the cardiovascular system. The model demonstrated good robustness (Supplementary Figure S6).

3.4.5 Low density lipoprotein cholesterol

The results for low density lipoprotein cholesterol (LDL-C) were comparable to those for total cholesterol (TC) and triglycerides (TG). There was no evidence of heterogeneity (l^2 =48%, p=0.09) or bias (Egger's test, p=0.9001, Supplementary Figure 2). The pooled results from six studies (n=364) indicated that the Ba Duan Jin exercise intervention significantly reduced participants' LDL cholesterol levels (Figure 6), which may have beneficial effects on the cardiovascular system (MD=-0.76, 95% CI=-0.92 to -0.60, p<0.01). The model demonstrated good robustness (Supplementary Figure S6).

3.4.6 High density lipoprotein cholesterol

Basic research has shown that high density lipoprotein cholesterol (HDL-C) functions as an anti-atherosclerotic and CVD preventive agent due to its ability to transport cholesterol in reverse, as well as its anti-inflammatory and antioxidant properties. There was considerable heterogeneity (I^2 = 69%, p = 0.0036) but no significant bias (Egger's test, p = 0.7870, Supplementary Figure S2) among the seven studies (n = 486). The combined results illustrated that the octopus exercise intervention significantly increased the participants' HDL-C levels and had a positive effect on the cardiovascular system (MD = 0.32, 95% CI = 0.14–0.51, p < 0.01) (Figure 6). A meta-regression analysis was conducted with age and the number of female participants as covariates. This analysis demonstrated that heterogeneity was partially explained (I^2 = 29.93%, p = 0.2322). The model demonstrated good robustness (Supplementary Figure S6).

3.4.7 Quality of life

Five of the 17 trials assessed the effects of the Ba Duan Jin exercise intervention on participants' anxiety and sleep quality. Three trials (n=223) used the Self-Assessment Scale for Anxiety (SAS) to assess participants before and after the intervention. There was no significant heterogeneity between studies ($I^2 = 61\%$, p = 0.0757) and no significant bias (Supplementary Figure S2). The results demonstrated that the Ba Duan Jin exercise intervention significantly reduced participants' anxiety (MD = -3.37, 95% CI = -3.84 to -2.89, p < 0.01) (Figure 7). The results were robust (Supplementary Figure S7).

Three trials (n=302) assessed participants' sleep quality before and after the intervention using the Pittsburgh Sleep Quality Index scale (PSQI). There was no significant inter-study heterogeneity (I^2 =59%, p=0.0896) or bias (Supplementary Figure S2). The results demonstrated that the Ba Duan Jin exercise intervention significantly improved participants' sleep quality (MD=-2.68, 95% CI=-3.63 to -1.73, p<0.01) (Figure 7). The results were robust (Supplementary Figure S7).

4 Discussion

Although there is considerable heterogeneity in the results of most studies, the present study's systematic review and meta-analysis of

Study	Experim Events					Weight (random)	Risk Ratio MH, Fixed + Random, 95% (I MH, Fixe	Risk Ratio	
1. Mortality										
Chongxing Wang 1994	31	122	57	120	37.7%	39.3%	0.53 [0.37, 0.76]		_	
Ankun Kuang 1986	18	104	32		21.4%	19.4%	0.54 [0.33, 0.90]			
Chongxing Wang 1991	35	154	62	152	40.9%	41.3%	0.56 [0.39, 0.79]	-	-	
Total (fixed effect, 95% CI)		380		372	100.0%		0.55 [0.44, 0.68]	-	-	
Total (random effect, 95% CI)						100.0%	0.55 [0.44, 0.68]	-	-	
Heterogeneity: Tau ² = 0; Chi ² = 0.0				%				[1	1
Test for overall effect (fixed effect)								0.5	1	2
Test for overall effect (random effe	ects): $Z = -$	5.31 (F	P < 0.01)							
2. Stroke mortality								:	E.	
Chongxing Wang 1994	19	122	39		36.7%	37.1%	0.48 [0.29, 0.78]	-		
Ankun Kuang 1986	12	104	23		21.9%	21.4%	0.50 [0.26, 0.95]			
Chongxing Wang 1991	22	154	44	152	41.4%	41.6%	0.49 [0.31, 0.78]		_	
Total (fixed effect, 95% CI)		380		372	100.0%		0.49 [0.36, 0.66]	-	-	
Total (random effect, 95% CI)						100.0%	0.49 [0.36, 0.66]	-	-	
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 0.0$				%				1	1	
Test for overall effect (fixed effect) Test for overall effect (random effe								0.5	1	2
3. MI mortality										
Chongxing Wang 1994	4	122	6	120	37.4%	39.4%	0.66 [0.19, 2.27]		-	
Ankun Kuang 1986	2	104	4	100	25.2%	21.6%	0.48 [0.09, 2.57]	1		
Chongxing Wang 1991	4	154	6	152	37.4%	39.0%	0.66 [0.19, 2.29]		-	
Total (fixed effect, 95% CI)		380		372	100.0%		0.61 [0.28, 1.33]			
Total (random effect, 95% CI)						100.0%	0.61 [0.28, 1.34]			
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 0.1$				%				I	1 1	
Test for overall effect (fixed effect) Test for overall effect (random effe								0.1	0.5 1 2	2 10
f Ba Duan Jin exercise on mo										

clinical research trials suggests that the Ba Duan Jin exercise intervention reduces mortality, improves cardiovascular health, and enhances quality of life in patients with cardiovascular systems. Furthermore, the study indicates that the Ba Duan Jin exercise intervention can have a positive effect on cardiovascular disease, regardless of the frequency or duration of the exercise.

Numerous research has indicated a strong association between hypertension and a higher risk of CVD, independent of other risk factors (42). High blood pressure is the primary modifiable risk factor globally, contributing to increased all-cause morbidity and mortality (43). Lifestyle modifications such as increased physical activity have proven to effectively lower blood pressure and prevent the onset of hypertension and its cardiovascular disease implications (44). Ba Duan Jin, a form of physical activity, has been shown to have significant antihypertensive benefits for individuals with hypertension, and it is well-liked by patients because it has minimal side effects (22, 45, 46). Additionally, a study has indicated that this intervention can effectively modulate cerebral hemodynamics, reduce blood pressure, and enhance the overall risk of ischemic stroke in older adults (47). In 12 of the 17 studies, participants were diagnosed with essential hypertension. Based on the results of our meta-analysis, it is evident that Ba Duan Jin exercise therapy has a significant antihypertensive effect on hypertension. Additionally, it may also have a positive impact on various cardiovascular and cerebrovascular susceptibility factors. These findings suggest that Ba Duan Jin exercise therapy could potentially play a role in preventing stroke and improving the prognosis of hypertension.

Blood lipids are significant predictors of the risk of atherosclerosis, coronary heart disease, and ischemic stroke (48-50). Dyslipidemia, which is characterized by abnormal lipid profiles, can lead to various health issues such as metabolic syndrome and cardiovascular disease (51-54). These profiles comprise high levels of total cholesterol (TC), high levels of triglycerides (TG), low levels of high-density lipoprotein cholesterol (HDL-C), and elevated levels of low-density lipoprotein cholesterol (LDL-C) (55). This study indicates that Ba Duan Jin exercise intervention can effectively reduce blood lipids, improve lipid metabolism, and alleviate clinical symptoms in patients with hyperlipidemia. Therefore, Ba Duan Jin exercise is highly recommended for preventing and treating hyperlipidemia. Furthermore, a study has demonstrated that the Ba Duan Jin exercise can significantly decrease the plasma levels of TC and LDL-C, while increasing the plasma level of HDL-C in healthy individuals. Additionally, the Ba Duan Jin exercise aids in regulating lipid metabolism in patients. These findings are in line with the results of the current study (56).

Sleep disorders have been associated with the development and advancement of various illnesses, including cardiovascular disease, depression, and cancer (57–59). Several factors can have a detrimental effect on sleep quality, such as stress and anxiety (60). Increasing evidence suggests that physical activity can significantly improve sleep quality (61). For instance, a meta-analysis has confirmed that qigong and tai chi exercises can reduce cardiometabolic risk factors, such as psychosocial stress, poor sleep quality, and weight gain. These exercises are particularly suitable for older individuals (62). In this study, we found that Ba Duan Jin exercise therapy can effectively reduce blood pressure and improve sleep quality. It has significant efficacy in treating hypertension with sleep disorders.

Huashan Pan 2010 -10.0000 1.9104 24 24 7.3% -10.00 [-13.74, -6.26] Liwei Zheng 2021-09 -2.9900 1.9365 38 38 7.3% -2.99 [-6.79, 0.81] Liwei Zheng 2021-03 -3.2900 2.2578 34 34 7.0% -3.29 [-7.72, 1.14] Weiying Fan 2021 -2.7800 1.5102 38 38 7.7% -2.78 [-5.74, 0.18] Zhanmei Huang 2021 -4.0400 1.2449 77 77 7.9% -4.04 [-6.48, -1.60] Yufeng Su 2012 -6.1200 3.1656 35 35 6.0% -6.12 [-12.32, 0.08] Yunhua Liang 2014 -7.8000 4.2725 30 30 4.8% -7.80 [-16.17, 0.57] Yujie Zhang 2023 -4.4400 2.4584 40 40 6.8% -4.44 [-9.26, 0.38] Weiwei Yang 2021 -7.0000 2.9709 34 33 6.2% -7.00 [-12.82, -1.18] Dezhi Chen 2016 -17.9000 4.3777 30 30 4.7% -17.90 [-26.48, -9.32] Chunmei Xiao 2016 -20.8000 4.6781 24 24 4.4% -20.80 [-29.97, -11.63] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.7% 10.20 [-1.62, 18.79] Filled: Xiaojun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 [-3.94, 22.27] Total (95% CI) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Chi ² = 76.67, df = 16 (P < 0.01); I ² = 79% Test for overall effect: Z = -2.85 (P < 0.01)	Study	MD	SE	IG Total	CG Total	Weight	Mean Differ IV, Random,		Mean Difference IV, Random, 95% CI	
Livei Zheng 2021-09 - 2.9900 1.9365 38 38 7.3% - 2.99 [-6.75, 0.81] Livei Zheng 2021-03 - 3.2900 2.576 34 34 7.7% - 3.29 [-7.72, 1.14] Weiying Fan 2021 - 4.0400 1.2449 77 77 7.9% -4.04 [-6.48, -1.60] Zhannel Huang 2021 - 4.0400 1.2449 77 77 7.9% -4.04 [-6.48, -1.61] Yunhua Liang 2014 - 7.8000 4.2725 30 30 4.8% -7.80 [-16.17, 0.57] Yunhua Liang 2014 - 7.0000 2.4584 40 40 6.8% -4.44 [-9.26, 0.38] Yunhua Liang 2014 - 7.0000 4.2725 30 30 4.8% -7.00 [-12.82, -1.18] Dezhi Chen 2016 -17.9000 4.3777 30 30 4.7% -7.09 [-26.48, -9.32] Filled: Yunhua Liang 2014 0.1049 4.3777 30 30 4.7% -7.09 [-26.48, -9.32] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Yunhua Liang 2016 10.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Yunhua Liang 2016 10.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Staipun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Dezhi Chen 2016 -17.2000 3.3204 24 24 4.4% 10.20 [1.62, 18.79] Filled: Staipun Ma 2022 3.600 1.249 4.3777 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 - 4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.0820 35 57 .76% -2.32 [-6.26, 1.62] Puiping Fan 2021 - 1.0000 1.6167 34 33 8.85% -1.00 [-4.17, 2.17] Filled: Xia0jun Ma 2022 - 7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yunhua Liang 2011 - 5.2000 2.9689 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 - 3.5400 0.6870 77 77 10.2% -3.54	1.Filled SBP									
Livei Zheng 2021-09 - 2.9900 1.9365 38 38 7.3% - 2.99 [-6.75, 0.81] Livei Zheng 2021-03 - 3.2900 2.576 34 34 7.7% - 3.29 [-7.72, 1.14] Weiying Fan 2021 - 4.0400 1.2449 77 77 7.9% -4.04 [-6.48, -1.60] Zhannel Huang 2021 - 4.0400 1.2449 77 77 7.9% -4.04 [-6.48, -1.61] Yunhua Liang 2014 - 7.8000 4.2725 30 30 4.8% -7.80 [-16.17, 0.57] Yunhua Liang 2014 - 7.0000 2.4584 40 40 6.8% -4.44 [-9.26, 0.38] Yunhua Liang 2014 - 7.0000 4.2725 30 30 4.8% -7.00 [-12.82, -1.18] Dezhi Chen 2016 -17.9000 4.3777 30 30 4.7% -7.09 [-26.48, -9.32] Filled: Yunhua Liang 2014 0.1049 4.3777 30 30 4.7% -7.09 [-26.48, -9.32] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Yunhua Liang 2016 10.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Yunhua Liang 2016 10.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Staipun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Dezhi Chen 2016 -17.2000 3.3204 24 24 4.4% 10.20 [1.62, 18.79] Filled: Staipun Ma 2022 3.600 1.249 4.3777 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 - 4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.3934 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 - 2.3500 2.0820 35 57 .76% -2.32 [-6.26, 1.62] Puiping Fan 2021 - 1.0000 1.6167 34 33 8.85% -1.00 [-4.17, 2.17] Filled: Xia0jun Ma 2022 - 7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yunhua Liang 2011 - 5.2000 2.9689 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 - 3.5400 0.6870 77 77 10.2% -3.54	Huashan Pan 2010	-10.0000	1.9104	24	24	7.3%	-10.00 [-13.74	-6.261		
Livei Zheng 2021-03 Weiying Fan 2021 2.7800 1.5102 Shammel Huag 2021 -2.7800 1.5102 38 38 7.7% -2.78 [-5.74, 0.18] -2.78 [-5.74, 0.18] -2.79 [-5.74, 0.16] -2.79 [-5.74, 0.17] -2.79 [-5.74, 0.17] -2.79 [-5.74, 0.16] -2.79 [-5.74, 0.17] -2.79 [-5.74, 0.17] -2.79 [-5.74, 0.17] -2.79 [-5.74, 0.17] -2.79 [-5.74, 0.17] -2.70 [-1.76] -2.70 [-1.76] -2.71	Liwei Zheng 2021-09	-2.9900	1.9365	38	38					
Weiying Fan 2021 -2.7800 1.5102 38 38 7.7% -2.78 [-5.74, 0.18] Zhanmei Huang 2021 -4.0400 1.2449 77 77 7.9% -4.04 [-6.48, -1.60] Yunhua Liang 2014 -7.8000 4.2725 30 30 4.8% -7.80 [-16.17, 0.57] Yunhua Liang 2023 -4.4400 2.4584 40 6.8% -4.44 [-9.26, 0.38] Weiwei Yang 2023 -4.4400 2.4584 40 6.8% -4.44 [-9.26, 0.38] Weiwei Yang 2021 -17.9000 4.3777 30 30 4.7% -7.79 [-26.48, -9.32] Chunnei Xiao 2016 -17.9000 4.781 24 24 4.3% -20.80 [-29.97, -11.63] Xiaojun Ma 2022 -11.3400 4.8062 34 32 4.3% -7.13 4 [-20.76, -1.92] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% -0.10 [-8.27, 84.8] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% -0.10 [-8.27, 84.8] Filled: Yunhua Liang 2016 1.0.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Xiaojun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Yunhua Liang 2016 1.0.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Yang 2021 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Yang 2021 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 44 .4% 13.10 [3.94, 22.27] Total (95% CI) 580 575 100.0% 4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Chi ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect 2 = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.66, -0.64] Weiwig Yang 2021 -0.23934 34 46 .6% -2.38 [-7.04, 2.34] Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwig Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiwig Yang 2021 -1.0000 0.6167 7 77 10.2% -3.54 [-4.67, 1.81] Yunhua Liang 2014 -5.2000 2.9688 30 30 5.6% -5.20 [-1.02, 0.52] Jammei Huag 2021 -3.5400 0.6670 37.77 10 2.9% -3.56 [-4.91, -2.17] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Filled: Dezhi Chen 2016 1.61676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Filled: Staojun Ma 2022 1.0	•									
Zhannei Huang 2021 - 4.0400 1.2449 77 77 7.9% -4.04 [-6.48, -1.60] Yufeng Su 2012 - 6.1200 3.1656 35 35 6.0% -6.12 [-12.32, 0.08] Weiwei Yang 2023 -4.4400 2.4584 40 40 6.8% -4.44 [-9.26, 0.38] Weiwei Yang 2021 -7.0000 2.9709 34 33 6.2% -7.00 [-12.82, -1.18] Dezhi Chen 2016 -20.8000 4.6781 24 24 4.4% -20.80 [-29.97, -11.68] Dezhi Chen 2016 -20.8000 4.6781 24 24 4.4% -20.80 [-29.97, -11.68] Dezhi Chen 2016 -20.8000 4.6781 24 24 4.4% -20.80 [-29.97, -11.68] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.7% 10.20 [-16.2, 18.79] Filled: Yunhua Liang 2016 13.1049 4.6781 24 24 4.4% 13.10 [3.94, 22.27] Total (95% CI) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Ch ² = 76.67, df = 16 (P < 0.01); l ² = 78% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -245] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Huashan Pan 2010 -4.2000 1.8657 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -0.1000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiwig Yang 2021 -1.4300 1.6537 38 88 8.4% -1.43 [-4.67, 1.81] Yufeng SU 2012 -2.32000 2.9598 30 30 5.6% -5.20 [-1.02, 0.62] Yufeng SU 2012 -3.5400 0.6870 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% -1.60 [-4.91, 7, 2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% -1.60 [-4.91, 7, 2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% -1.60 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% -1.60 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% -1.60 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7, 11] Filled: Ziaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.91, -2.17] Filled: Siaoj										
Yufeng Su 2012 - 6.120 3.1656 35 35 6.0% -6.12[-12.32, 0.06] Yunhua Liang 2014 -7.8000 4.2725 30 30 4.8% -7.80 [-16.17, 0.57] Yunig Zhang 2023 -4.400 2.4584 40 40 6.8% -4.44 [-9.26, 0.38] Weiwei Yang 2021 -7.0000 2.9709 34 33 6.2% -7.00 [-12.82, -1.18] Dezhi Chen 2016 -17.9000 4.3777 30 30 4.7% -17.90 [-26.48, -9.32] Chunmei Xiao 2016 -20.8000 4.6781 24 24 4.4% -20.80 [-29.97, -11.63] Tilled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2010 2.3049 1.9104 24 24 7.3% 2.30 [-1.44, 6.05] Filled: Yunhua Liang 2010 2.3049 1.9104 24 24 7.3% 2.30 [-1.44, 6.05] Filled: Yunhua Liang 2016 10.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 [3.94, 22.27] Total (95% CI) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Chi ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.07 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, 0.54] Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-1.89, -2.45] Huashan Pan 2010 -4.2000 1.8657 74 24 7.9% -4.20 [-8.26, 0.54] Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 38 8.5% -1.00 [-4.17, 2.17] Weiwing Fan 2021 -1.4300 0.16537 38 38 8.4% -4.43 [-6.76, 1.81] Tilled: Chunmei Xiao 2016 1.7339 40 40 8.2% -4.62 [-8.20, -1.24] Weiwing Tan 2021 -1.4300 0.66970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yunipu Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.52 [-7.95, -1.15] Thane Huang 2021 -3.5400 0.66970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Chunmei Xiao 2016 10.6676 3.3024 24 4 5.0% 10.67 [-4.97, 7.11] Filled: Chunmei Xiao 2016 10.6676 3.3024 24 4 5.0% 10.67 [-4.91, -2.17] Filled: Chunmei Xia									-	
Yunhua Liang 2014 7.8000 4.2725 30 30 4.8% 7.80 $\begin{bmatrix} -16.17, 0.57 \\ 3.88 \\ 4.44 \\ [-9.26, 0.38] \\ Weiwel Yang 2021 7.0000 2.9709 4 33 6.2% 7.001 \begin{bmatrix} -12.82, -1.18 \\ -20.800 \\ -20.800 \\ 4.78 \\ -7.901 \\ -20.800 \\ 4.78 \\ -7.901 \\ -20.800 \\ -20.800 \\ 4.78 \\ -7.901 \\ -20.800 \\ $							and the second se			
Yujie Zhang 2023 -4.400 2.4584 40 40 6.8% -4.44 [-9.26, 0.38] Weiwei Yang 2021 -7.0000 2.9709 34 33 6.2% -7.00 [-12.82, -1.18] Dezhi Chen 2016 -7.0900 4.3777 30 30 4.7% -7.30 [-26.48, -9.32] Chunmei Xiao 2016 -20.8000 4.6781 24 24 4.4% -20.80 [-29.97, -11.63] Xiaojun Ma 2022 -11.3400 4.8062 34 32 4.3% -11.34 [-20.76, -1.92] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.4% 0.10 [-8.27, 8.48] Filled: Xiaojun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Xiaojun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Chen 2016 10.2049 4.3777 30 30 4.7% 10.20 [-16.2, 18.79] Filled: Chen 2016 10.2049 4.3777 30 30 4.7% 10.20 [-16.2, 18.79] Filled: Chen 2016 13.1049 4.6781 24 24 4.4% 13.10 [3.94, 22.27] Total (95% CI) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Ch ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiwing Fan 2021 -1.4000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiwing Fan 2021 -1.4000 1.6377 38 38 8.4% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -3.5400 0.6870 77 77 10.2% -3.54 [-4.91, -2.17] Yujie Zhang 2023 -4.6500 1.7339 40 40 8.2% -4.65 [-7.95, -1.15] Yujie Zhang 2021 -3.5400 0.6870 377 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.3204 24 24 5.0% 10.67 [-4.97, 7.11] Filled: Xiaojun Ma 2022 1.0676 3.3204 24 24 5.0% 10.67 [-4.97, 7.11] Filled: Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [-4.97, 7.11] Filled: Chunmei Xiao 2016 10.6676 3.3204 24										
Weiwei Yang 2021 -7.0000 2.9709 34 33 $6.2\% -7.00 [-12.82, -1.18]$ Dezhi Chen 2016 -17.9000 4.3777 30 30 4.7% -17.90 [-26.48, -9.32] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2010 2.3049 1.9104 24 24 7.3% 2.300 [-1.44, 6.05] Filled: Liashan Pan 2010 2.3049 4.3777 30 30 4.7% 10.20 [-1.62, 18.79] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 [-3.94, 22.27] Total (95% CI) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Chi ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021 -03 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwing Fan 2021 -1.0000 1.6167 3 38 38 8.4% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-1.364, -1.56] Yufeng Stu 2012 -2.3200 2.0082 35 5.76% -2.32 [-6.26, 1.62] Yufeng Stu 2012 -3.3500 2.9688 30 30 5.6% -5.20 [-11.02, 0.62] Yufeng Xu 2012 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiao 2016 1.6676 3.3204 24 24 2.4 0.% 1.067 [-4.16, 12.41] Filled: Xiao 2016 1.6676 3.3204 24 24 2.4% -1.067 [-4.97, 7.11] Filled: Xiao 2016 1.6676 3.3204 24 24 2.4% -4.55 [-7.95, -1.16] Yufung Xiao 2012 -3.5400 0.6970 77 77 10.2% -3.54 [-4.97, 7.11] Filled: Chunmei Xiao 2016 1.6676 3.3204 24 24 5.0% 10.67 [-4.68, 12.41] Filled: Xiaojun Ma 2022 1.0576 3.8019 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Chunmei Xiao 2016 1.06676 3.8019 34 32 5.4% 1.067 [-4.97, 7.11] Filled: Chunmei Xiao 2016 1.06676 3.9204 24 24 5.0% 10.67 [-4.68, 12.41] Filled: Chunmei Xiao 2016 1.06676 3.9204 24 24 5.0% 10.67 [-4.98, 12.41] Fill										
Dezhi Chen 2016 -17.9000 4.3777 30 30 4.7% -17.90 [-26.48, -9.32] Chunmei Xiao 2016 -20.8000 4.6781 24 24 4.4% -20.80 [-29.97, -11.63] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Huashan Pan 2010 2.3049 1.9104 24 24 7.3% 2.30 [-1.44, 6.05] Filled: Yunhua Liang 2016 10.2049 4.3777 30 30 4.7% 10.20 [-6.24, 18.79] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 [3.94, 22.27] Total (95% Cl) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907: Chi ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 -4.6200 1.7249 83 88.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiwing Fan 2021 -1.4300 1.6577 38 38 8.4% -1.43 [-4.67, 1.81] Yunhua Liang 2011 -4.52000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Yujie Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.65 [-7.56, -1.15] Yufeng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yujie Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.65 [-7.95, -1.15] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73%										
Chunmei Xiao 2016 -20.8000 4.6781 24 24 4.4% -20.80 [-29.97, -11.63] Xiaojun Ma 2022 -11.3400 4.8062 34 32 4.3% -11.34 [-20.76, -1.92] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Xiaojun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 [-5.77, 13.06] Filled: Xiao 2016 10.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 [3.94, 22.27] Total (95% Cl) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Chi ² = 76.67, df = 16 ($P < 0.01$); $I2 = 79%$ Test for overall effect: Z = -2.85 ($P < 0.01$) Z-Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Livei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Livei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Yufeng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yufneg Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yufneg Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yufneg Su 2012 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yufneg Su 2012 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0319 34 32 5.4% -7.60 [-13.64, -1.56] Yufneg Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [-4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Ch ² = 50.98, df = 14 ($P < 0.01$); $I2 = 73\%$	•						•			
Xiaojun Ma 2022 -11.3400 4.8062 34 32 4.3% -11.34 [-20.76, -1.92] Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Huashan Pan 2010 2.3049 1.9104 24 24 7.3% 2.30 [-1.44, 6.05] Filled: Huashan Pan 2012 10.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 [3.94, 22.27] Total (95% CI) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Ch ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: $Z = -2.85$ (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021 -1.0000 1.6167 34 33 8.5% -4.62 [-8.00, -1.24] Weiwign Fan 2021 -1.0000 1.6167 34 33 8.5% -4.62 [-8.00, -1.24] Weiwign Fan 2021 -1.0000 1.6167 34 33 8.5% -4.62 [-8.00, -1.24] Weiwign Fan 2021 -1.0000 1.6167 34 33 8.5% -5.20 [-11.02, 0.62] Yunhua Ling 2014 -5.2000 2.9688 30 30 5.6% -5.20 [-1.102, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yufing Su 2012 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0319 34 32 5.4% -7.60 [-13.64, -1.56] Total (95% CI) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Ch ² = 50.98, df = 14 (P < 0.01); l ² = 73%										
Filled: Yunhua Liang 2014 0.1049 4.2725 30 30 4.8% 0.10 [-8.27, 8.48] Filled: Huashan Pan 2010 2.3049 1.9104 24 24 7.3% 2.30 [-1.44, 6.05] Filled: Liang 2014 0.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 [3.94, 22.27] Total (95% Cl) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Ch ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-03 -2.3500 2.3934 34 33 8.8.5% -1.00 [-4.17, 2.17] Weiwing Fan 2021 -1.4000 1.6167 34 38 8.8.5% -1.00 [-4.17, 2.17] Weiwing Fan 2021 -1.4000 1.6167 38 38 8.4.5% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yufeng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -7.62 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -7.62 [-1.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.08, 12.41] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Ch ² = 50.98, df = 14 (P < 0.01); l ² = 73%										
Filled: Huashan Pan 2010 2.3049 1.9104 24 24 7.3% 2.30 $\begin{bmatrix} -1.44, 6.05 \end{bmatrix}$ Filled: Xiaojun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 $\begin{bmatrix} -5.77, 13.06 \end{bmatrix}$ Filled: Dezhi Chen 2016 10.2049 4.3777 30 30 4.7% 10.20 $\begin{bmatrix} 1.62, 18.79 \end{bmatrix}$ Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 $\begin{bmatrix} 3.94, 22.27 \end{bmatrix}$ Total (95% Cl) 580 575 100.0% -4.05 $\begin{bmatrix} -6.84, -1.26 \end{bmatrix}$ Heterogeneity: Tau ² = 23.907; Ch ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 $\begin{bmatrix} -23.71, -10.69 \end{bmatrix}$ Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 $\begin{bmatrix} -18.95, -2.45 \end{bmatrix}$ Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 $\begin{bmatrix} -7.86, -0.54 \end{bmatrix}$ Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 $\begin{bmatrix} -7.04, 2.34 \end{bmatrix}$ Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.452 $\begin{bmatrix} -7.04, 2.34 \end{bmatrix}$ Liwei Zheng 2021 -03 -4.6200 1.7249 38 88 8.2% -4.62 $\begin{bmatrix} -8.00, -1.24 \end{bmatrix}$ Weiwig Fan 2021 -1.4300 1.6537 38 38 8.4% -1.43 $\begin{bmatrix} 4.67, 1.81 \end{bmatrix}$ Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 $\begin{bmatrix} -13.64, -1.56 \end{bmatrix}$ Yufeng Su 2012 -2.3200 2.0828 35 7.6% -2.32 $\begin{bmatrix} -6.26, 1.62 \end{bmatrix}$ Yufeng Su 2012 -2.3200 2.9698 30 30 5.6% -5.20 $\begin{bmatrix} -1.102, 0.62 \end{bmatrix}$ Zhanmei Huang 2021 -3.5400 0.6970 77 77 71 0.2% -3.54 $\begin{bmatrix} -4.91, -2.17 \end{bmatrix}$ Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 $\begin{bmatrix} 4.91, -2.17 \end{bmatrix}$ Total (95% Cl) 526 521 100.0% -3.21 $\begin{bmatrix} -5.22, -1.20 \end{bmatrix}$										
Filled: Xiaojun Ma 2022 3.6449 4.8062 34 32 4.3% 3.64 $[-5.77, 13.06]$ Filled: Dezhi Chen 2016 10.2049 4.3777 30 30 4.7% 10.20 $[-1.62, 18.79]$ Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 $[-3.94, 22.27]$ Total (95% CI) 580 575 100.0% -4.05 $[-6.84, -1.26]$ Heterogeneity: Tau ² = 23.907; Ch ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 $[-23.71, -10.69]$ Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 $[-18.95, -2.45]$ Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 $[-7.86, -0.54]$ Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 $[-7.04, 2.34]$ Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 $[-7.04, 2.34]$ Liwei Zheng 2021 -1.0000 1.6167 34 38 8.8% -1.00 $[-4.77, 2.17]$ Weiwing Fan 2021 -1.4300 1.6537 38 38 8.4% -1.43 $[-4.67, 1.81]$ Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 $[-13.64, -1.56]$ Yufeng Su 2012 -2.3200 2.082 35 35 7.6% -2.32 $[-6.26, 1.62]$ Yujie Zhang 2021 -3.5400 0.6970 77 77 710.2% -3.54 $[-4.91, -2.17]$ Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 $[-4.97, 7.11]$ Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 $[-4.9, 7, 7.11]$ Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 $[-4.9, 7, 1.12]$ Total (95% CI) 526 521 100.0% -3.21 $[-5.22, -1.20]$									Tan-	
Filled: Dezhi Chen 2016 10.2049 4.3777 30 30 4.7% 10.20 [1.62, 18.79] Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 [3.94, 22.27] Total (95% CI) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Chi ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiying Fan 2021 -1.4300 1.6537 38 38 8.4% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 - 7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yuteng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yujie Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% CI) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73%										
Filled: Chunmei Xiao 2016 13.1049 4.6781 24 24 4.4% 13.10 $\begin{bmatrix} 3.94, 22.27 \end{bmatrix}$ Total (95% CI) 580 575 100.0% -4.05 [-6.84, -1.26] Heterogeneity: Tau ² = 23.907; Chi ² = 76.67, df = 16 (P < 0.01); l ² = 79% Test for overall effect Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.4300 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiying Fan 2021 -1.4300 1.6167 38 38 8.4% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yufeng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yujie Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yuhuna Liang 2014 -5.2000 2.9698 30 30 5.6% -5.232 [-6.26, 1.62] Yujie Zhang 2021 -0.667 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% CI) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73%										
Total (95% CI)580575100.0%-4.05 [-6.84, -1.26]Heterogeneity: Tau ² = 23.907; Chi ² = 76.67, df = 16 (P < 0.01); l ² = 79%Test for overall effect: Z = -2.85 (P < 0.01)2.Filled DBPChunmei Xiao 2016-17.20003.320424245.0%-17.20[-23.71, -10.69]Dezhi Chen 2016-17.20003.320424245.0%-17.20[-23.71, -10.69]Dezhi Chen 2016-10.70004.207930303.8%-10.70[-18.95, -2.45]Huashan Pan 2010-4.20001.865724247.9%-4.20[-7.86, -0.54]Livei Zheng 2021-03-2.35002.393434346.8%-2.35[-7.04, 2.34]Livei Zheng 2021-03-2.35002.393434346.8%-2.35[-7.04, 2.34]Livei Zheng 2021-03-2.35002.393434346.8%-2.35[-7.04, 2.34]Weivei Yang 2021-1.00001.616734338.5%-1.00[-4.17, 2.17]Weiving Fan 2021-1.43001.653738888.4%-1.43[-4.67, 1.81]Yuife Zhang 2023-4.55001.733940408.2%-2.05[-1.10.2]0.62]Zhanmei Huang 2021-3.54000.6970777710.2%-3.54[-4.91, -2.										
Heterogeneity: $Tau^2 = 23.907$; $Chi^2 = 76.67$, $df = 16$ (P < 0.01); $I^2 = 79\%$ Test for overall effect: Z = -2.85 (P < 0.01) 2.Filled DBP Chunmei Xiao 2016 -17.2000 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiying Fan 2021 -1.4300 1.6537 38 38 8.4% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yufeng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yuje Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yuhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [-4.16, 17.18] Total (95% CI) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); I ² = 73%								,		
Chunmei Xiao 2016 -17.200 3.3204 24 24 5.0% -17.20 [-23.71, -10.69] Dezhi Chen 2016 -10.7000 4.2079 30 30 3.8% -10.70 [-18.95, -2.45] Huashan Pan 2010 -4.2000 1.8657 24 24 7.9% -4.20 [-7.86, -0.54] Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiying Fan 2021 -1.4300 1.6537 38 38 8.4% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yufeng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yuje Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [-4.16, 17.18] Total (95% CI) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73%	Heterogeneity: Tau ² = 23.907						4.00 [0.04,	1.20]	-20 -10 0 10 20	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2.Filled DBP								1.0	
Huashan Pan 20104.2000 1.8657247.9%4.20[-7.86, -0.54]Liwei Zheng 2021-03-2.3500 2.3934346.8%-2.35[-7.04, 2.34]Liwei Zheng 2021-09-4.6200 1.724938388.2%-4.62[-8.00, -1.24]Weiwei Yang 2021-1.0000 1.616734338.5%-1.00[-4.17, 2.17]Weiwei Yang 2021-1.4300 1.6537388.8.4%-1.467, 1.81]Xiaojun Ma 2022-7.6000 3.08193425.4%-1.66Yuipe Zhang 2023-4.5500 1.7339408.2%-4.55-1.15]Yuipe Zhang 2023-4.5500 1.7339408.2%-4.55-7.11Yuipe Zhang 2021-3.5400 0.6970777710.2%-3.54-4.97, 7.11]Filled: Xiaojun Ma 20221.0676 3.081934325.4%1.07-4.97, 7.11]Filled: Chunmei Xiao 20161.0676 3.320424 <td colspan<="" td=""><td>Chunmei Xiao 2016</td><td>-17.2000</td><td>3.3204</td><td>24</td><td>24</td><td>5.0%</td><td>-17.20 [-23.71,</td><td>-10.69]</td><td></td></td>	<td>Chunmei Xiao 2016</td> <td>-17.2000</td> <td>3.3204</td> <td>24</td> <td>24</td> <td>5.0%</td> <td>-17.20 [-23.71,</td> <td>-10.69]</td> <td></td>	Chunmei Xiao 2016	-17.2000	3.3204	24	24	5.0%	-17.20 [-23.71,	-10.69]	
Liwei Zheng 2021-03 -2.3500 2.3934 34 34 6.8% -2.35 [-7.04, 2.34] Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiying Fan 2021 -1.4300 1.6537 38 38 8.4% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yuje Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% CI) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); I ² = 73%	Dezhi Chen 2016	-10.7000	4.2079	30	30	3.8%	-10.70 [-18.95	, -2.45]		
Liwei Zheng 2021-09 -4.6200 1.7249 38 38 8.2% -4.62 [-8.00, -1.24] Weiwei Yang 2021 -1.0000 1.6167 34 33 8.5% -1.00 [-4.17, 2.17] Weiying Fan 2021 -1.4300 1.6537 38 38 8.4% -1.43 [-4.67, 1.81] Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yufeng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yujie Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% CI) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); I ² = 73%	Huashan Pan 2010	-4.2000	1.8657	24	24	7.9%	-4.20 [-7.86,	-0.54]		
Weiwei Yang 2021 $-1.0000 \ 1.6167$ 34 33 8.5% $-1.00 \ [-4.17, \ 2.17]$ Weiying Fan 2021 $-1.4300 \ 1.6537$ 38 38 8.4% $-1.43 \ [-4.67, \ 1.81]$ Xiaojun Ma 2022 $-7.6000 \ 3.0819$ 34 32 5.4% $-7.60 \ [-13.64, \ -1.56]$ Yufeng Su 2012 $-2.3200 \ 2.0082$ 35 35 7.6% $-2.32 \ [-6.26, \ 1.62]$ Yufeng Su 2012 $-2.3200 \ 2.0082$ 35 35 7.6% $-2.32 \ [-6.26, \ 1.62]$ Yuhua Liang 2013 $-4.5500 \ 1.7339$ 40 8.2% $-4.55 \ [-7.95, \ -1.15]$ Yunhua Liang 2014 $-5.2000 \ 2.9698$ 30 30 5.6% $-5.20 \ [-11.02, \ 0.62]$ Zhanmei Huang 2021 $-3.5400 \ 0.6970$ 77 77 10.2% $-3.54 \ [-4.91, \ -2.17]$ Filled: Xiaojun Ma 2022 $1.0676 \ 3.0819$ 34 32 5.4% $1.07 \ [-4.97, \ 7.11]$ Filled: Dezhi Chen 2016 $4.1676 \ 4.2079$ 30 30 3.8% $4.17 \ [-4.08, \ 12.41]$ Filled: Chunmei Xiao 2016 $10.6676 \ 3.3204$ 24 24 5.0% $10.67 \ [-4.16, \ 17.18]$ Total (95% Cl) 526521 100.0% $-3.21 \ [-5.22, \ -1.20]$ Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73\%	Liwei Zheng 2021-03	-2.3500	2.3934	34	34	6.8%	-2.35 [-7.04,	2.34]		
Weiying Fan 2021-1.4300 1.653738388.4%-1.43 [-4.67, 1.81]Xiaojun Ma 2022-7.6000 3.081934325.4%-7.60 [-13.64, -1.56]Yufeng Su 2012-2.3200 2.008235357.6%-2.32 [-6.26, 1.62]Yujie Zhang 2023-4.5500 1.733940408.2%-4.55 [-7.95, -1.15]Yunhua Liang 2014-5.2000 2.969830305.6%-5.20 [-11.02, 0.62]Zhanmei Huang 2021-3.5400 0.6970777710.2%-3.54 [-4.91, -2.17]Filled: Xiaojun Ma 20221.0676 3.081934325.4%1.07 [-4.97, 7.11]Filled: Dezhi Chen 20164.1676 4.2079303.8%4.17 [-4.08, 12.41]Filled: Chunmei Xiao 201610.6676 3.320424245.0%10.67 [4.16, 17.18]Total (95% CI)526521 100.0%-3.21 [-5.22, -1.20]Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); I ² = 73%	Liwei Zheng 2021-09	-4.6200	1.7249	38	38	8.2%	-4.62 [-8.00,	-1.24]		
Xiaojun Ma 2022 -7.6000 3.0819 34 32 5.4% -7.60 [-13.64, -1.56] Yufeng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yujie Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73%	Weiwei Yang 2021	-1.0000	1.6167	34	33	8.5%	-1.00 [-4.17,	2.17]		
Yuteng Su 2012 -2.3200 2.0082 35 35 7.6% -2.32 [-6.26, 1.62] Yujie Zhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Dezhi Chen 2016 4.1676 4.2079 30 30 3.8% 4.17 [-4.08, 12.41] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] • Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73% 73% - - -	Weiying Fan 2021	-1.4300	1.6537	38						
Yujie Žhang 2023 -4.5500 1.7339 40 40 8.2% -4.55 [-7.95, -1.15] Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.97, 7.11] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Chen 2016 4.1676 4.2079 30 30 3.8% 4.17 [-4.08, 12.41] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73% -3.36	Xiaojun Ma 2022	-7.6000	3.0819	34	32	5.4%	-7.60 [-13.64,	-1.56]		
Yunhua Liang 2014 -5.2000 2.9698 30 30 5.6% -5.20 [-11.02, 0.62] Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Dezhi Chen 2016 4.1676 4.2079 30 30 3.8% 4.17 [-4.08, 12.41] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); I ² = 73% -3.21 [-5.22, -1.20]	Yufeng Su 2012	-2.3200	2.0082	35	35	7.6%	-2.32 [-6.26,	1.62]		
Zhanmei Huang 2021 -3.5400 0.6970 77 77 10.2% -3.54 [-4.91, -2.17] Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Dezhi Chen 2016 4.1676 4.2079 30 30 3.8% 4.17 [-4.08, 12.41] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73% -3.21 [-5.22, -1.20]		-4.5500	1.7339	40						
Filled: Xiaojun Ma 2022 1.0676 3.0819 34 32 5.4% 1.07 [-4.97, 7.11] Filled: Dezhi Chen 2016 4.1676 4.2079 30 30 3.8% 4.17 [-4.08, 12.41] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73% -3.21 [-5.22, -1.20]	Yunhua Liang 2014	-5.2000	2.9698	30	30	5.6%	-5.20 [-11.02,	0.62]		
Filled: Dezhi Chen 2016 4.1676 4.2079 30 30 3.8% 4.17 [-4.08, 12.41] Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73%	Zhanmei Huang 2021	-3.5400	0.6970	77	77	10.2%	-3.54 [-4.91,	-2.17]		
Filled: Chunmei Xiao 2016 10.6676 3.3204 24 24 5.0% 10.67 [4.16, 17.18] Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73% -3.21	Filled: Xiaojun Ma 2022	1.0676	3.0819	34	32	5.4%	1.07 [-4.97,	7.11]		
Total (95% Cl) 526 521 100.0% -3.21 [-5.22, -1.20] Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); I^2 = 73%	Filled: Dezhi Chen 2016	4.1676	4.2079	30	30	3.8%	4.17 [-4.08,	12.41]		
Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73%	Filled: Chunmei Xiao 2016	10.6676	3.3204	24	24	5.0%	10.67 [4.16,	17.18]		
Heterogeneity: Tau ² = 9.813; Chi ² = 50.98, df = 14 (P < 0.01); l ² = 73%	Total (95% CI)			526	521	100.0%	-3.21 [-5.22.	-1.201	•	
		Chi ² = 50.9	8. df = 14							
									-20 -10 0 10 20	

To our knowledge, no other systematic review including only randomized controlled trials has been conducted with the specific aim of examining the effects of Ba Duan Jin in adults for the primary prevention of cardiovascular disease (CVD). Therefore, it is difficult to make comparisons with other similar studies at this time. The focus of this review was specifically on the Ba Duan Jin exercise intervention in order to minimize the influence of other behavioral interventions on the results. This approach was taken to narrow down the number of trials eligible for inclusion. However, it is important to note that the limited number of trials, along with their methodological limitations and unclear risk of bias, significantly restrict the conclusions that can be drawn from this review.

5 Strengths and limitations

This is the first meta-analysis examining the effects of Ba Duan Jin exercise intervention for the primary prevention of cardiovascular diseases. Our evidence may provide researchers with new ideas and promote more experimental protocols. This study can encourage the public to choose effective and appropriate exercise methods to prevent cardiovascular diseases.

The current review indicates that further trials are required to elucidate the potential benefits of Ba Duan Jin exercise therapy for cardiovascular disease (CVD) risk factors. Furthermore, as all the literature included was conducted in China, there is a lack of data support from validated clinical trials in countries other than China, which may have limited the generalization of the results.

6 Conclusion

This conclusion is divided into two main sections.

The first section focuses on the implications for practice. At present, the evidence base for Ba Duan Jin exercise therapy in the context of primary CVD prevention is limited. The trials included in this review were few in number for relevant outcomes and small in sample size, and were at significant risk of bias. Consequently, there

Study		G D Total	Mean	CG			Weight (random) IV.	Mean Difference Fixed + Random, 95% CI	Mean Difference IV, Fixed + Random, 95% CI
	incari c	Dirotai	mean	00	Total	(inxed)	(random) iv,		
1.Total Cholesterol									1
Chunmei Xiao 2016	-1.40 0.90			0.6671	24		11.5%	-1.39 [-1.84, -0.94]	
Dezhi Chen 2016	-0.80 0.86			0.8602	30		11.7%	-0.80 [-1.24, -0.36]	
Huashan Pan 2010	-1.31 0.84			0.6671	25		11.9%	-0.95 [-1.37, -0.53]	
Peng Sha 2010	-1.01 0.78			0.9502 1.3091	24 40	9.9% 7.8%	10.9%	-1.30 [-1.79, -0.81]	
Xiaojun Ma 2022 Yufeng Su 2012	-0.44 1.21			0.9795	32	9.4%	10.0%	-0.59 [-1.14, -0.04]	
Fusheng Miao 2009				0.9263	35		12.1%	0.00 [-0.51, 0.51]	
Yunhua Liang 2014	-0.61 0.81			1.2681	30	6.4%	9.2%	-0.67 [-1.08, -0.26] -0.94 [-1.55, -0.33]	
Zhanmei Huang 2021	-0.27 1.40			1.2307		13.8%	12.0%	-0.37 [-0.79, 0.05]	
Total (fixed effect, 95% CI)		319			317	100.0%		-0.78 [-0.93, -0.62]	•
Total (random effect, 95% Cl) Heterogeneity: $Tau^2 = 0.126$; Chi ²		(P<00	1): $I^2 = 6$	9%			100.0%	-0.78 [-1.06, -0.50]	
Test for overall effect (fixed effect) Test for overall effect (random effect)): Z = -9.84 (P	< 0.01)		570					-1.5 -1 -0.5 0 0.5 1 1.5
2. Triglycerides									- · ·
Chunmei Xiao 2016	-0.64 0.99	9 24	0.07	0.8323	24	4.2%	4.2%	-0.71 [-1.23, -0.19]	
Dezhi Chen 2016	-0.27 1.16	1 30	0.09	1.0348	30	3.6%	3.6%	-0.36 [-0.92, 0.20]	
Fusheng Miao 2009	-0.28 0.26	0 25	0.01	0.3041	25		44.7%	-0.29 [-0.45, -0.13]	
Huashan Pan 2010	-0.54 0.71	51 24	-0.32	0.7790	24	6.2%	6.2%	-0.22 [-0.64, 0.20]	
Peng Sha 2010	-0.42 0.46		0.08	0.5664	40		21.6%	-0.50 [-0.73, -0.27]	
Xiaojun Ma 2022	-0.36 0.91			0.8637	32	6.0%	6.0%	-0.64 [-1.07, -0.21]	
Yufeng Su 2012	-0.24 1.05			0.4319	35	7.8%	7.8%	-0.29 [-0.67, 0.09]	
Yunhua Liang 2014	-1.72 0.97			1.0526	30	4.2%	4.2%	-0.67 [-1.18, -0.16]	
Zhanmei Huang 2021	-0.13 1.24	6 77	0.13	3.5083	77	1.6%	1.6%	-0.26 [-1.09, 0.57]	
Total (fixed effect, 95% CI) Total (random effect, 95% CI)		319			317	100.0%	100.0%	-0.39 [-0.49, -0.28] -0.39 [-0.49, -0.28]	±
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 7.5$ Test for overall effect (fixed effect) Test for overall effect (random effect)	36, df = 8 (P =): Z = -7.20 (P	< 0.01)							-1 -0.5 0 0.5 1
3.LDL-C									- 1 1
Chunmei Xiao 2016	-1.34 1.07			1.0821	24	6.8%	11.2%	-1.38 [-1.99, -0.77]	
Dezhi Chen 2016	-0.82 1.13			0.7860	30		14.8%	-0.85 [-1.34, -0.36]	
Fusheng Miao 2009	-0.38 0.61			0.6859	25		20.5%	-0.37 [-0.73, -0.01]	
Peng Sha 2010	-0.81 0.50			0.5659	40		27.6%	-0.86 [-1.10, -0.62]	
Xiaojun Ma 2022 Yunhua Liang 2014	-0.46 1.112			0.9860	32 30	10.0%	14.3% 11.7%	-0.67 [-1.18, -0.16] -0.62 [-1.21, -0.03]	
	1.00 1.10		0.01	1.1040					
Total (fixed effect, 95% CI) Total (random effect, 95% CI)		183			181	100.0%	100.0%	-0.76 [-0.92, -0.60] -0.76 [-1.01, -0.52]	•
Heterogeneity: $Tau^2 = 0.042$; Chi^2 Test for overall effect (fixed effect) Test for overall effect (random effect)): Z = -9.35 (P	< 0.01)		3%					-1 0 1
I.HDL-C									
Chunmei Xiao 2016	0.28 0.83	6 24	0.01	0.8417	24	3.9%	9.4%	0.27 [-0.21, 0.75]	
Dezhi Chen 2016	0.22 0.99			0.9633	30	3.6%	8.9%	0.23 [-0.27, 0.73]	
Fusheng Miao 2009	0.39 0.33			0.3041	25		19.3%	0.40 [0.22, 0.58]	
Huashan Pan 2010	0.17 0.72			0.8301	24	4.5%	10.2%	0.13 [-0.31, 0.57]	
Xiaojun Ma 2022	0.62 0.48			0.5412		14.3%	16.6%	0.70 [0.45, 0.95]	
Yunhua Liang 2014	0.51 0.56			0.5235		11.6%	15.6%	0.36 [0.09, 0.63]	
Zhanmei Huang 2021	0.02 0.50			0.5021		34.3%	20.0%	0.08 [-0.08, 0.24]	
Total (fixed effect, 95% Cl) Total (random effect, 95% Cl) Heterogeneity: $Tau^2 = 0.040$; Chi^2	= 19.36, df = 0		1); I ² = 6	9%	242	100.0%	100.0%	0.31 [0.21, 0.40] 0.32 [0.14, 0.51]	
Test for overall effect (fixed effect) Test for overall effect (random effect))						-0.5 0 0.5
URE 6									

is very low confidence in the validity of the results. The clinical event data provided by three trials many years after completion of the trials as originally designed may not be attributable to the intervention, and thus no firm conclusions can be drawn on the basis of their findings. Similarly, alterations in cardiovascular disease (CVD) risk factors may be attributable to suboptimal trial conduct. Consequently, no definitive conclusions can be drawn.

The results of our study demonstrated that Ba Duan Jin exercise has a beneficial effect on patients with essential hypertension through a meta-analysis and systematic evaluation of existing clinical trials. Furthermore, it has been demonstrated to enhance lipid profiles and cardiovascular function in older adult patients with hyperlipidemia. These findings indicate that Ba Duan Jin exercise therapy may be a promising intervention for the primary prevention of cardiovascular disease. In order to ascertain whether Ba Duan Jin exercise represents an efficacious lifestyle intervention for the prevention of CVD, it is necessary to await the publication of further trial evidence derived from methodologically rigorous, adequately powered, long-term trials. It is therefore premature to make any recommendations regarding practice at this stage.

The second section focuses on the implications for research. The current research landscape shows a limited number of RCTs focused

Study	Mean	IG SD	Total	Mean	CG			Weight (random)	Mean Difference V, Fixed + Random, 95% Cl	Mean Difference IV, Fixed + Random, 95% CI
Liwei Zheng 2021-03	-5.35	2.8711	34	-1.47	3.8726	34	34.2%	33.8%	-3.88 [-5.50, -2.26]	
Yujie Zhang 2023	-6.43	3.8865	40	-3.48	4.3236	40	27.7%	30.9%	-2.95 [-4.75, -1.15]	
Zhanmei Huang 2021	-1.31	4.6502	77	0.10	5.0580	77	38.1%	35.3%	-1.41 [-2.94, 0.12]	
Total (fixed effect, 95% CI)			151			151	100.0%		-2.68 [-3.63, -1.73]	•
Total (random effect, 95% CI)								100.0%	-2.72 [-4.20, -1.24]	-
Test for overall effect (fixed effect Test for overall effect (random effect .PSQI				1)						-4 -2 0 2 4
	0.00	4 4 4 5 0	-		4 0745	-	04 501	54.000	0.171.0.07.0.071	<u></u>
Weiying Fan 2021		1.1459			1.0715	38		54.2%	-3.47 [-3.97, -2.97]	
Yujie Zhang 2023		9.0810			9.6922	40		12.1%	-5.72 [-9.84, -1.60]	
Weiwei Yang 2021	-10.11	3.6167	33	-8.50	3.8161	34	7.2%	33.7%	-1.61 [-3.39, 0.17]	
Total (fixed effect, 95% CI)			111			112	100.0%	•	-3.37 [-3.84, -2.89]	•
Total (random effect, 95% CI)								100.0%	-3.12 [-4.73, -1.50]	
Heterogeneity: Tau ² = 1.186; Chi ²				$ ^2 = 61$	%					1 1 1
Test for overall effect (fixed effect)										-5 0 5
Test for overall effect (random effe	ects): Z =	= -3.78 (F	< 0.01)						
RE 7										

solely on evaluating the effectiveness of Ba Duan Jin exercise for the primary prevention of CVD. There is a particular scarcity of large, rigorously conducted RCTs with extended follow-up periods that specifically investigate the effectiveness of Ba Duan Jin exercise for the prevention of major CVD events and CVD risk factors. Additionally, there is a lack of evidence regarding the effectiveness of Ba Duan Jin exercise in populations outside of China. Furthermore, there is a notable absence of information on the incidence of Type 2 Diabetes (T2D) in relation to the intervention, as well as any potential adverse effects and costs associated with the implementation of Ba Duan Jin exercise.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

JC: Methodology, Writing – original draft, Writing – review & editing, Formal analysis, Investigation. MZ: Methodology, Writing – original draft, Formal analysis, Investigation, Writing – review & editing. YW: Data curation, Formal analysis, Investigation, Writing – original draft. ZZ: Conceptualization, Data curation, Software, Writing – original draft. SG: Data curation, Formal analysis, Writing – original draft. YZ: Funding acquisition, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was

supported by Hebei Province Higher Education Teaching Reform Research and Practice Project (Project No. 2022GJJG606) and Hebei Medical University Education and Teaching Research Project (Project No. 2020YBZDX-6).

Acknowledgments

The authors are grateful to all the participants who were involved in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2024.1425843/ full#supplementary-material

References

1. Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. *N Engl J Med.* (2023) 389:1273–85. doi: 10.1056/NEJMoa2206916

2. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. *Nat Rev Cardiol.* (2018) 15:215–29. doi: 10.1038/nrcardio.2017.189

3. Strain T, Brage S, Sharp SJ, Richards J, Tainio M, Ding D, et al. Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity: a descriptive study. *Lancet Glob Health*. (2020) 8:e920–30. doi: 10.1016/ s2214-109x(20)30211-4

4. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. *Lancet.* (2020) 395:795–808. doi: 10.1016/s0140-6736(19)32008-2

5. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *J Am Coll Cardiol*. (2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010

6. Song Y, Li J, István B, Xuan R, Wei S, Zhong G, et al. Current evidence on traditional Chinese exercises for quality of life in patients with essential hypertension: a systematic review and Meta-analysis. *Front Cardiovasc Med.* (2020) 7:627518. doi: 10.3389/ fcvm.2020.627518

7. Song Y, Sun D, István B, Thirupathi A, Liang M, Teo EC, et al. Current evidence on traditional Chinese exercise for cancers: a systematic review of randomized controlled trials. *Int J Environ Res Public Health*. (2020) 17:5011. doi: 10.3390/ijerph17145011

8. Channon KM. Exercise and cardiovascular health: new routes to reap more rewards. *Cardiovasc Res.* (2020) 116:e56–8. doi: 10.1093/cvr/cvz264

9. Fiuza-Luces C, Santos-Lozano A, Joyner M, Carrera-Bastos P, Picazo O, Zugaza JL, et al. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. *Nat Rev Cardiol.* (2018) 15:731–43. doi: 10.1038/s41569-018-0065-1

10. Valenzuela PL, Ruilope LM, Santos-Lozano A, Wilhelm M, Kränkel N, Fiuza-Luces C, et al. Exercise benefits in cardiovascular diseases: from mechanisms to clinical implementation. *Eur Heart J*. (2023) 44:1874–89. doi: 10.1093/eurheartj/ehad170

11. Zou L, Pan Z, Yeung A, Talwar S, Wang C, Liu Y, et al. A review study on the beneficial effects of Baduanjin. *J Altern Complement Med.* (2018) 24:324–35. doi: 10.1089/acm.2017.0241

12. Zhang Y, Jiang X. The effect of Baduanjin exercise on the physical and mental health of college students: a randomized controlled trial. *Medicine (Baltimore)*. (2023) 102:e34897. doi: 10.1097/md.00000000034897

13. Liu J, Yang Y, Zhu Y, Hou X, Li S, Chen S, et al. Effectiveness of Baduanjin (a type of qigong) on physical, cognitive, and mental health outcomes: a comprehensive review. *Adv Mind Body Med.* (2023) 37:9–23.

14. Lin H, Wan M, Ye Y, Zheng G. Effects of Baduanjin exercise on the physical function of middle-aged and elderly people: a systematic review and meta-analysis of randomized controlled trials. *BMC Complement Med Ther*. (2023) 23:38. doi: 10.1186/s12906-023-03866-4

15. Sun W, Zhang XA, Wang Z. The role and regulation mechanism of Chinese traditional fitness exercises on the bone and cartilage tissue in patients with osteoporosis: a narrative review. *Front Physiol.* (2023) 14:1071005. doi: 10.3389/fphys.2023.1071005

16. Yao KR, Luo Q, Tang X, Wang ZH, Li L, Zhao L, et al. Effects of traditional Chinese mind-body exercises on older adults with cognitive impairment: a systematic review and meta-analysis. *Front Neurol.* (2023) 14:1086417. doi: 10.3389/fneur.2023.1086417

17. Bidaurrazaga-Letona I, Ayán C, Duñabeitia I, Esain I, Monasterio X, Zulueta B, et al. Effect of Baduanjin on physical functioning and balance in adults with mild-tomoderate intellectual disabilities: a comparative study. *J Appl Res Intellect Disabil*. (2023) 36:768–76. doi: 10.1111/jar.13092

18. Lu Y, Li J, Ni W, Li J, Song J, Jiang J, et al. Effectiveness of mind-body exercise via Baduanjin on physical and psychological outcomes in patients with pulmonary groundglass nodules: a non-randomized controlled pilot study. *Complement Ther Clin Pract.* (2023) 50:101679. doi: 10.1016/j.ctcp.2022.101679

19. Wei L, Liu Y, Wang Y, Bian J, Song Z, Liu X, et al. The effects of Baduanjin on physical function, daily living activities and quality of life in patients with stroke: a systematic review and meta-analysis. *Top Stroke Rehabil.* (2024) 31:178–98. doi: 10.1080/10749357.2023.2238433

20. Jones C, Qi M, Xie Z, Moyle W, Weeks B, Li P. Baduanjin exercise for adults aged 65 years and older: a systematic review and Meta-analysis of randomized controlled studies. *J Appl Gerontol.* (2022) 41:1244–56. doi: 10.1177/07334648211059324

21. Luo X, Zhao M, Zhang Y, Zhang Y. Effects of baduanjin exercise on blood glucose, depression and anxiety among patients with type II diabetes and emotional disorders: a meta-analysis. *Complement Ther Clin Pract.* (2023) 50:101702. doi: 10.1016/j. ctcp.2022.101702

22. Ma Z, Lei H, Tian K, Liu Z, Chen Y, Yang H, et al. Baduanjin exercise in the treatment of hypertension: a systematic review and meta-analysis. *Front Cardiovasc Med.* (2022) 9:936018. doi: 10.3389/fcvm.2022.936018

23. Bugni WJ, Ayers CW, Ashby R, Bittle PA, Ramirez G. Effects of dilevalol on rest and supine exercise hemodynamics in mild to moderate systemic hypertension. *Am J Cardiol.* (1989) 63:452–6. doi: 10.1016/0002-9149(89)90318-4

24. Guan Y, Hao Y, Guan Y, Wang H. Effects of Baduanjin exercise on essential hypertension: a meta-analysis of randomized controlled trials. *Medicine (Baltimore)*. (2020) 99:e21577. doi: 10.1097/md.00000000021577

25. Sha P. The influence of fitness qigong Wuqinxi on blood lipid index and balance ability of middle-aged and old women. *Shaanxi J Tradit Chin Med.* (2010) 31:1332–5.

26. Su YF, Liu XD. Influence of fitness qigong Yi Jinjing exercise on body function and blood lipid in the elderly. *J Nanjing Sports Inst.* (2012) 11:27–9. doi: 10.15877/j.cnki. nsin.2012.02.021

27. Miao FS, Liu XY, Li Y, Wang XC. Effect of fitness qigong Baduanjin on blood lipid and lipoprotein metabolism in patients with hyperlipidemia. *J Shandong Inst Phys Educ Sports.* (2009) 25:46–8. doi: 10.14104/j.cnki.1006-2076.2009.10.013

28. Ma X, Li M, Liu L, Lei F, Wang L, Xiao W, et al. A randomized controlled trial of Baduanjin exercise to reduce the risk of atherosclerotic cardiovascular disease in patients with prediabetes. *Sci Rep.* (2022) 12:19338. doi: 10.1038/s41598-022-22896-5

29. Fan WY, Zheng LW, Chen F, Zou LY, Rao YL, Fang XH. Effect of Baduanjin exercise on anxiety and depression in 38 elderly patients with essential hypertension. *Fujian J Tradit Chin Med.* (2021) 52:11–3. doi: 10.13260/j.cnki.jfjtcm.012171

30. Yang WW, Zheng SC. Effect of badJin on negative mood and self-efficacy in community elderly hypertensive patients. *China Foreign Med Treat*. (2021) 40:168–72. doi: 10.16662/j.cnki.1674-0742.2021.35.168

31. Zheng LW, Fan WY, Zou LY, Chen F, Rao YL, Fang XH. Effect of Baduanjin on elderly patients with hypertension with frailty. *J Nurs Sci.* (2021) 36:90–93+97.

32. Zheng LW, Liu WH, Zo LY, Fan WY, Chen F. Effect of Baduanjin on sleep quality in elderly patients with essential hypertension associated with insomnia. *J Guangxi Univ Chin Med.* (2021) 24:33–7.

33. Pan HS, Feng YC. Clinical observation of the rehabilitation treatment of grade 1 hypertension in the elderly. *J Nanjing Sports Inst.* (2010) 9:4–6. doi: 10.15877/j.cnki. nsin.2010.01.006

34. Huang ZM, Wu X, Zeng LH, Hu SY, Peng D, Zou ZY. Observation on the application effect of Baduanjin in health management of patients with grade 1. *Jiangxi J Tradit Chin Med.* (2021) 52:34–7.

35. Chen D. Effect of health qigong Mawangdui Daoyinshu on blood pressure of individuals with essential hypertension. *J Am Geriatr Soc.* (2016) 64:1513–5. doi: 10.1111/jgs.14218

36. Liang YH, Liao SQ, Han CL, Wang H, Peng Y. Effect of Baduanjin exercise intervention on blood pressure and blood lipid in patients with essential hypertension. *Henan Tradit Chin Med.* (2014) 34:2380-1. doi: 10.16367/j. issn.1003-5028.2014.12.102

37. Xiao C, Yang Y, Zhuang Y. Effect of health qigong Ba Duan Jin on blood pressure of individuals with essential hypertension. *J Am Geriatr Soc.* (2016) 64:211–3. doi: 10.1111/jgs.13913

38. Zhang YJ. Effect of Baduanjin exercise on blood pressure control, psychological state and sleep quality in elderly hypertensive patients. *Chin Sci Technol J Database Med.* (2023) 2023:0001–4.

39. Kuang AK, Wang CX, Xu DH, Zhao GS, Qian YS, Jiang MD, et al. Qigong treatment of 204 patients with hypertension in 20 years of comparative observation of curative effect, prognosis and related mechanism. *J Integr Tradit West Med.* (1986):9–12+2.

40. Wang CX, Xu DH, Qian YS, Shi W, Huang JF. Study on qigong prevention of hypertensive stroke and its mechanism (30-year follow-up data of 242 hypertensive patients). *Chin J Gerontol.* (1994):90–2.

41. Wang CX, Xu DH, Qian YS, Dong SQ, Kuang AK. Comparative observation of the long-term efficacy of qigong to prevent and treat hypertension – 306 patients with 25 to 30 years of follow-up. *J Shanghai Second Med Univ.* (1991):93–6.

42. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA*. (2003) 289:2560–72. doi: 10.1001/jama.289.19.2560

43. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. *Nat Rev Dis Primers*. (2018) 4:18014. doi: 10.1038/nrdp.2018.14

44. Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. (2022) 328:1849-61. doi: 10.1001/jama.2022.19590

45. Shao BY, Zhang XT, Vernooij RWM, Lv QY, Hou YY, Bao Q, et al. The effectiveness of Baduanjin exercise for hypertension: a systematic review and meta-analysis of randomized controlled trials. *BMC Complement Med Ther.* (2020) 20:304. doi: 10.1186/s12906-020-03098-w

46. Xiong X, Wang P, Li S, Zhang Y, Li X. Effect of Baduanjin exercise for hypertension: a systematic review and meta-analysis of randomized controlled trials. *Maturitas*. (2015) 80:370–8. doi: 10.1016/j.maturitas.2015.01.002 47. Zheng G, Chen B, Fang Q, Lin Q, Tao J, Chen L. Baduanjin exercise intervention for community adults at risk of ischamic stroke: a randomized controlled trial. *Sci Rep.* (2019) 9:1240. doi: 10.1038/s41598-018-37544-0

48. Abedi F, Sadeghi M, Omidkhoda N, Kelesidis T, Ramezani J, Samadi S, et al. HDLcholesterol concentration and its association with coronary artery calcification: a systematic review and meta-analysis. *Lipids Health Dis.* (2023) 22:60. doi: 10.1186/ s12944-023-01827-x

49. Gao Y, Yu L, Li X, Yang C, Wang A, Huang H. The effect of different traditional Chinese exercises on blood lipid in middle-aged and elderly individuals: a systematic review and network Meta-analysis. *Life (Basel)*. (2021) 11:714. doi: 10.3390/life11070714

50. Li S, Hou L, Zhu S, Yi Q, Liu W, Zhao Y, et al. Lipid variability and risk of cardiovascular diseases and all-cause mortality: a systematic review and meta-analysis of cohort studies. *Nutrients*. (2022) 14:2450. doi: 10.3390/nu14122450

51. Liu C, Dhindsa D, Almuwaqqat Z, Ko YA, Mehta A, Alkhoder AA, et al. Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations. *JAMA Cardiol.* (2022) 7:672–80. doi: 10.1001/jamacardio.2022.0912

52. Sergi D, Zauli E, Tisato V, Secchiero P, Zauli G, Cervellati C. Lipids at the Nexus between cerebrovascular disease and vascular dementia: the impact of HDL-cholesterol and ceramides. *Int J Mol Sci.* (2023) 24:4403. doi: 10.3390/ijms24054403

53. Trimarco V, Izzo R, Morisco C, Mone P, Virginia Manzi M, Falco A, et al. High HDL (high-density lipoprotein) cholesterol increases cardiovascular risk in hypertensive patients. *Hypertension*. (2022) 79:2355–63. doi: 10.1161/hypertensionaha.122.19912

54. Zhou Z, Ong KL, Whelton SP, Allison MA, Curtis AJ, Blaha MJ, et al. Impact of blood lipids on 10-year cardiovascular risk in individuals without dyslipidemia and with low risk factor burden. *Mayo Clin Proc.* (2022) 97:1883–93. doi: 10.1016/j. mayocp.2022.03.025

55. Abdullah SM, Defina LF, Leonard D, Barlow CE, Radford NB, Willis BL, et al. Long-term Association of low-Density Lipoprotein Cholesterol with Cardiovascular Mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. *Circulation*. (2018) 138:2315–25. doi: 10.1161/circulationaha.118.034273

56. Mei L, Chen Q, Ge L, Zheng G, Chen J. Systematic review of chinese traditional exercise baduanjin modulating the blood lipid metabolism. *Evid Based Complement Alternat Med.* (2012) 2012:282131. doi: 10.1155/2012/282131

57. Kwok CS, Kontopantelis E, Kuligowski G, Gray M, Muhyaldeen A, Gale CP, et al. Self-reported sleep duration and quality and cardiovascular disease and mortality: a dose-response Meta-analysis. *J Am Heart Assoc.* (2018) 7:e008552. doi: 10.1161/jaha.118.008552

58. Sejbuk M, Mirończuk-Chodakowska I, Witkowska AM. Sleep quality: a narrative review on nutrition, stimulants, and physical activity as important factors. *Nutrients.* (2022) 14:1912. doi: 10.3390/nu14091912

59. Wang X, Wang R, Zhang D. Bidirectional associations between sleep quality/ duration and multimorbidity in middle-aged and older people Chinese adults: a longitudinal study. *BMC Public Health*. (2024) 24:708. doi: 10.1186/s12889-024-17954-8

60. Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. Improving sleep quality leads to better mental health: a meta-analysis of randomised controlled trials. *Sleep Med Rev.* (2021) 60:101556. doi: 10.1016/j.smrv.2021.101556

61. Shi L, He F, Wu F, Ren Y, Xiong M, Wu Y, et al. Serial mediation effect of physical activity and sleep quality between dietary behaviour and depression symptoms: a nationwide cross-sectional survey. *J Glob Health.* (2024) 14:04081. doi: 10.7189/jogh.14.04081

62. Rameshkumar R, Larkey L, Alperin K, Martin D, Primus A, James D. Study design exploring qigong and tai chi easy (QTC) on cardiometabolic risk factors. *Contemp Clin Trials*. (2022) 118:106793. doi: 10.1016/j.cct.2022.106793